Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial
Titel:
Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial
Auteur:
Zhou, Qing Chen, Ming Jiang, Ou Pan, Yi Hu, Desheng Lin, Qin Wu, Gang Cui, Jiuwei Chang, Jianhua Cheng, Yufeng Huang, Cheng Liu, Anwen Yang, Nong Gong, Youling Zhu, Chuan Ma, Zhiyong Fang, Jian Chen, Gongyan Zhao, Jun Shi, Anhui Lin, Yingcheng Li, Guanghui Liu, Yunpeng Wang, Dong Wu, Rong Xu, Xinhua Shi, Jianhua Liu, Zhihua Cui, Na Wang, Jingru Wang, Qiang Zhang, Ran Yang, Jason Wu, Yi-Long